{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T16:57:07Z","timestamp":1791046627589,"version":"4.1.0"},"reference-count":54,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Randomized clinical trials have shown that sacubitril-valsartan reduces the risks of mortality and hospitalization in patients with heart failure with reduced ejection fraction (HFrEF), but patients with kidney failure requiring dialysis were excluded.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To investigate the comparative effectiveness of sacubitril-valsartan vs angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (ACEIs or ARBs) in patients with HFrEF requiring hemodialysis.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This retrospective, 1:1 propensity score\u2013matched comparative effectiveness study included patients who were 18 years or older with HFrEF, enrolled in Medicare Parts A, B, and D, and survived at least 90 days receiving in-center hemodialysis from July 8, 2015, to December 31, 2020. Patients were excluded for less than 180 days of continuous Medicare Parts A, B, and D primary payer coverage or prior dispensing of sacubitril-valsartan. Data analysis was conducted from September 23, 2023, to June 25, 2024.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n New use of sacubitril-valsartan vs new or continued use of ACEIs or ARBs.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The associations between initiation of sacubitril-valsartan therapy and all-cause mortality, cardiovascular mortality, all-cause hospitalization, and HF hospitalization were assessed using Cox proportional hazards regression models in a propensity score\u2013matched sample.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Participants included 1:1 matched pairs of 1434 sacubitril-valsartan users and 1434 ACEI or ARB users (mean [SD] age, 64 [13] years). Of the 2868 matched participants, 996 (65%) were male; 987 (34%) were Black or African American and 1677 (58%) were White; and median dialysis vintage was 3.8 (IQR, 1.8-6.3) years. The median follow-up was 0.9 (IQR, 0.4-1.7) years. Sacubitril-valsartan (vs ACEI or ARB) therapy was associated with a reduction in all-cause mortality (hazard ratio [HR], 0.82 [95% CI, 0.73-0.92]) and all-cause hospitalization (HR, 0.86 [95% CI, 0.79-0.93]) but not cardiovascular mortality (HR, 1.01 [95% CI, 0.86-1.19]) or HF hospitalization (HR, 0.91 [95% CI, 0.82-1.02]). There was a decrease in hyperkalemia (HR, 0.71 [95% CI, 0.62-0.81]) and no difference in hypotension (HR, 0.99 [95% CI, 0.83-1.19]). Only 195 participants (14%) ever received the maximum combination dose of sacubitril (97 mg twice daily) and valsartan (103 mg twice daily).<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this comparative effectiveness study of patients with HFrEF requiring hemodialysis, sacubitril-valsartan therapy was associated with beneficial effects in all-cause mortality and all-cause hospitalization.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.29237","type":"journal-article","created":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T11:03:40Z","timestamp":1724151820000},"page":"e2429237","source":"Crossref","is-referenced-by-count":28,"title":["Sacubitril-Valsartan in Patients Requiring Hemodialysis"],"prefix":"10.1001","volume":"7","author":[{"given":"Dustin","family":"Le","sequence":"first","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan E.","family":"Grams","sequence":"additional","affiliation":[{"name":"Division of Precision Medicine, Department of Medicine, New York University, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef","family":"Coresh","sequence":"additional","affiliation":[{"name":"Optimal Aging Institute, Department of Medicine, New York University, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Im","family":"Shin","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,8,20]]},"reference":[{"issue":"11","key":"zoi240886r2","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure.","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"issue":"10","key":"zoi240886r3","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure.","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"issue":"21","key":"zoi240886r4","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction.","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"issue":"18","key":"zoi240886r5","doi-asserted-by":"publisher","first-page":"e895","DOI":"10.1161\/CIR.0000000000001063","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines.","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"issue":"1","key":"zoi240886r6","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jchf.2019.08.003","article-title":"Comparative effectiveness of sacubitril-valsartan versus ACE\/ARB therapy in heart failure with reduced ejection fraction.","volume":"8","author":"Tan","year":"2020","journal-title":"JACC Heart Fail"},{"issue":"5","key":"zoi240886r7","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.119.044586","article-title":"Sacubitril\/valsartan across the spectrum of ejection fraction in heart failure.","volume":"141","author":"Solomon","year":"2020","journal-title":"Circulation"},{"issue":"8","key":"zoi240886r8","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1001\/jamacardio.2019.2223","article-title":"Assessment of national coverage and out-of-pocket costs for sacubitril\/valsartan under Medicare Part D.","volume":"4","author":"DeJong","year":"2019","journal-title":"JAMA Cardiol"},{"issue":"6","key":"zoi240886r9","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1001\/jamacardio.2016.1747","article-title":"Cost-effectiveness analysis of sacubitril\/valsartan vs enalapril in patients with heart failure and reduced ejection fraction.","volume":"1","author":"Gaziano","year":"2016","journal-title":"JAMA Cardiol"},{"issue":"8","key":"zoi240886r12","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1002\/clc.v46.8","article-title":"Effects of sacubitril-valsartan in the treatment of chronic heart failure patients with end-stage renal disease undergoing dialysis.","volume":"46","author":"Liu","year":"2023","journal-title":"Clin Cardiol"},{"key":"zoi240886r13","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.794707","article-title":"Angiotensin receptor-neprilysin inhibitors in patients with heart failure with reduced ejection fraction and advanced chronic kidney disease: a retrospective multi-institutional study.","volume":"9","author":"Hsiao","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"3","key":"zoi240886r14","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1002\/ehf2.v7.3","article-title":"Sacubitril\/valsartan in patients with heart failure with reduced ejection fraction with end-stage of renal disease.","volume":"7","author":"Lee","year":"2020","journal-title":"ESC Heart Fail"},{"issue":"1","key":"zoi240886r15","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1111\/tap.v26.1","article-title":"Effect of sacubitril-valsartan on cardiac function in hemodialysis patients.","volume":"26","author":"Daimon","year":"2022","journal-title":"Ther Apher Dial"},{"issue":"1","key":"zoi240886r16","doi-asserted-by":"publisher","DOI":"10.1080\/0886022X.2023.2222841","article-title":"Effects of sacubitril-valsartan in patients undergoing maintenance dialysis.","volume":"45","author":"Ding","year":"2023","journal-title":"Ren Fail"},{"issue":"18","key":"zoi240886r17","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.026407","article-title":"Sacubitril\/valsartan in patients with heart failure and concomitant end-stage kidney disease.","volume":"11","author":"Niu","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"zoi240886r18","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.657067","article-title":"Effects of sacubitril-valsartan in heart failure with preserved ejection fraction in patients undergoing peritoneal dialysis.","volume":"8","author":"Fu","year":"2021","journal-title":"Front Med (Lausanne)"},{"issue":"5","key":"zoi240886r19","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1159\/000531217","article-title":"Study on the efficacy of sacubitril\/valsartan in patients with heart failure with preserved ejection fraction undergoing peritoneal dialysis.","volume":"148","author":"Sheng","year":"2023","journal-title":"Cardiology"},{"issue":"7","key":"zoi240886r20","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1002\/pds.v20.7","article-title":"Validity of claims-based definitions of left ventricular systolic dysfunction in Medicare patients.","volume":"20","author":"Li","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"zoi240886r21","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.117.004302","article-title":"Adoption of sacubitril\/valsartan for the management of patients with heart failure.","volume":"11","author":"Sangaralingham","year":"2018","journal-title":"Circ Heart Fail"},{"issue":"8","key":"zoi240886r22","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available.","volume":"183","author":"Hern\u00e1n","year":"2016","journal-title":"Am J Epidemiol"},{"issue":"6","key":"zoi240886r23","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1056\/NEJMoa1812851","article-title":"Angiotensin-neprilysin inhibition in acute decompensated heart failure.","volume":"380","author":"Velazquez","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"zoi240886r24","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/ki.2009.413","article-title":"An improved comorbidity index for outcome analyses among dialysis patients.","volume":"77","author":"Liu","year":"2010","journal-title":"Kidney Int"},{"key":"zoi240886r25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v042.i08","article-title":"MatchIt: nonparametric preprocessing for parametric causal inference.","volume":"42","author":"Ho","year":"2011","journal-title":"J Stat Softw"},{"issue":"12","key":"zoi240886r26","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1093\/aje\/kwj149","article-title":"Variable selection for propensity score models.","volume":"163","author":"Brookhart","year":"2006","journal-title":"Am J Epidemiol"},{"issue":"8","key":"zoi240886r27","doi-asserted-by":"publisher","first-page":"S84","DOI":"10.1016\/j.jclinepi.2013.01.013","article-title":"Prognostic score-based balance measures can be a useful diagnostic for propensity score methods in comparative effectiveness research.","volume":"66","author":"Stuart","year":"2013","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"zoi240886r28","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12874-017-0338-0","article-title":"Double-adjustment in propensity score matching analysis: choosing a threshold for considering residual imbalance.","volume":"17","author":"Nguyen","year":"2017","journal-title":"BMC Med Res Methodol"},{"issue":"4","key":"zoi240886r29","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: introducing the E-value.","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann Intern Med"},{"issue":"27","key":"zoi240886r30","doi-asserted-by":"publisher","first-page":"4391","DOI":"10.1002\/sim.v36.27","article-title":"Practical recommendations for reporting Fine-Gray model analyses for competing risk data.","volume":"36","author":"Austin","year":"2017","journal-title":"Stat Med"},{"issue":"2","key":"zoi240886r33","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1053\/j.ajkd.2010.03.020","article-title":"Association of residual urine output with mortality, quality of life, and inflammation in incident hemodialysis patients: the Choices for Healthy Outcomes in Caring for End-Stage Renal Disease (CHOICE) Study.","volume":"56","author":"Shafi","year":"2010","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"zoi240886r34","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1002\/ejhf.2019.21.issue-3","article-title":"Reduced loop diuretic use in patients taking sacubitril\/valsartan compared with enalapril: the PARADIGM-HF trial.","volume":"21","author":"Vardeny","year":"2019","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"zoi240886r35","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s12874-020-00947-7","article-title":"An evaluation of inverse probability weighting using the propensity score for baseline covariate adjustment in smaller population randomised controlled trials with a continuous outcome.","volume":"20","author":"Raad","year":"2020","journal-title":"BMC Med Res Methodol"},{"issue":"7","key":"zoi240886r36","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nrrheum.2015.30","article-title":"Active-comparator design and new-user design in observational studies.","volume":"11","author":"Yoshida","year":"2015","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"zoi240886r37","doi-asserted-by":"publisher","first-page":"161","DOI":"10.3390\/toxins12030161","article-title":"Cardiac remodeling in chronic kidney disease.","volume":"12","author":"Kaesler","year":"2020","journal-title":"Toxins (Basel)"},{"issue":"1","key":"zoi240886r38","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1159\/000520466","article-title":"Causes of death in end-stage kidney disease: comparison between the United States Renal Data System and a large integrated health care system.","volume":"53","author":"Bhandari","year":"2022","journal-title":"Am J Nephrol"},{"issue":"2","key":"zoi240886r39","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1053\/j.ajkd.2016.09.015","article-title":"Dialysate potassium, serum potassium, mortality, and arrhythmia events in hemodialysis: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS).","volume":"69","author":"Karaboyas","year":"2017","journal-title":"Am J Kidney Dis"},{"issue":"11","key":"zoi240886r40","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1093\/qjmed\/hcx118","article-title":"Impact of admission serum potassium on mortality in patients with chronic kidney disease and cardiovascular disease.","volume":"110","author":"Cheungpasitporn","year":"2017","journal-title":"QJM"},{"issue":"38","key":"zoi240886r41","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.1093\/eurheartj\/ehx460","article-title":"Associations of serum potassium levels with mortality in chronic heart failure patients.","volume":"38","author":"Aldahl","year":"2017","journal-title":"Eur Heart J"},{"issue":"3","key":"zoi240886r42","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1159\/000479802","article-title":"Association of serum potassium with all-cause mortality in patients with and without heart failure, chronic kidney disease, and\/or diabetes.","volume":"46","author":"Collins","year":"2017","journal-title":"Am J Nephrol"},{"issue":"3","key":"zoi240886r43","doi-asserted-by":"publisher","first-page":"244","DOI":"10.3390\/kidneydial3030022","article-title":"The impact of potassium binders on mortality in patients with hyperkalemia: a single-center study.","volume":"3","author":"Nagasu","year":"2023","journal-title":"Kidney Dial"},{"issue":"41","key":"zoi240886r44","doi-asserted-by":"publisher","first-page":"4362","DOI":"10.1093\/eurheartj\/ehac401","article-title":"Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial.","volume":"43","author":"Butler","year":"2022","journal-title":"Eur Heart J"},{"issue":"1","key":"zoi240886r45","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1053\/j.ajkd.2016.10.024","article-title":"Serum potassium and short-term clinical outcomes among hemodialysis patients: impact of the long interdialytic interval.","volume":"70","author":"Brunelli","year":"2017","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"zoi240886r46","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1053\/j.ajkd.2017.01.044","article-title":"Race, serum potassium, and associations with ESRD and mortality.","volume":"70","author":"Chen","year":"2017","journal-title":"Am J Kidney Dis"},{"issue":"8","key":"zoi240886r47","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1002\/ejhf.v22.8","article-title":"Unravelling the interplay between hyperkalaemia, renin-angiotensin-aldosterone inhibitor use and clinical outcomes: data from 9222 chronic heart failure patients of the ESC-HFA-EORP Heart Failure Long-Term Registry.","volume":"22","author":"Rossignol","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"11","key":"zoi240886r48","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1002\/ejhf.v22.11","article-title":"Serum potassium in the PARADIGM-HF trial.","volume":"22","author":"Ferreira","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"zoi240886r49","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.jjcc.2019.03.010","article-title":"Sacubitril\/valsartan in heart failure with reduced ejection fraction patients: real world experience on advanced chronic kidney disease, hypotension, and dose escalation.","volume":"74","author":"Chang","year":"2019","journal-title":"J Cardiol"},{"issue":"1","key":"zoi240886r50","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1136\/hrt.2007.134973","article-title":"Quantifying the paradoxical effect of higher systolic blood pressure on mortality in chronic heart failure.","volume":"95","author":"Raphael","year":"2009","journal-title":"Heart"},{"issue":"18","key":"zoi240886r51","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1001\/jama.296.18.2217","article-title":"Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure.","volume":"296","author":"Gheorghiade","year":"2006","journal-title":"JAMA"},{"issue":"16","key":"zoi240886r52","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1016\/j.jacc.2022.08.737","article-title":"Dose-response to sacubitril\/valsartan in patients with heart failure and reduced ejection fraction.","volume":"80","author":"Mohebi","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"zoi240886r53","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1002\/ejhf.2016.18.issue-10","article-title":"Efficacy of sacubitril\/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial.","volume":"18","author":"Vardeny","year":"2016","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"zoi240886r54","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1093\/aje\/kwr301","article-title":"Bias in observational studies of prevalent users: lessons for comparative effectiveness research from a meta-analysis of statins.","volume":"175","author":"Danaei","year":"2012","journal-title":"Am J Epidemiol"},{"key":"zoi240886r1","volume-title":"2021 USRDS Annual Data Report: Epidemiology of Kidney Disease in the United States","author":"U.S. Renal Data System","year":"2021"},{"key":"zoi240886r32","volume-title":"Stata Statistical Software: Release 17","author":"StataCorp","year":"2021"},{"key":"zoi240886r10","unstructured":"Efficacy and Safety of Sacubitril\/Valsartan in Maintenance Hemodialysis Patients With Heart Failure (ESARHD-HF). ClinicalTrials.gov Identifier NCT04458285. Updated October 6, 2020. Accessed December 31, 2022. https:\/\/clinicaltrials.gov\/study\/NCT04458285"},{"key":"zoi240886r11","unstructured":"The Effect of Sacubitril\/Valsartan on Cardiovascular Events Outcome in Maintenance Dialysis Patients With Heart Failure and Efficacy Prediction of Baseline LVEF Value. ClinicalTrials.gov Identifier NCT4572724. Updated October 8, 2020. Accessed December 31, 2022. https:\/\/clinicaltrials.gov\/study\/NCT04572724"},{"key":"zoi240886r31","unstructured":"R Core Team. R: A language and environment for statistical computing. R Program for Statistical Computing; 2020. Accessed September 23, 2023. https:\/\/www.R-project.org\/"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2822448\/le_2024_oi_240886_1723229492.37192.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T11:03:46Z","timestamp":1724151826000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2822448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,20]]},"references-count":54,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.29237","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,20]]}}}